These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26216350)

  • 21. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours.
    Kim TH; Kim YK; Kwon Y; Heo JH; Kang H; Kim G; An HJ
    Histopathology; 2010 Nov; 57(5):734-43. PubMed ID: 21083603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNAs in breast cancer pathogenesis.
    Götte M
    Minerva Ginecol; 2010 Dec; 62(6):559-71. PubMed ID: 21079577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status on microRNAs as biomarkers for ovarian cancer.
    Prahm KP; Novotny GW; Høgdall C; Høgdall E
    APMIS; 2016 May; 124(5):337-55. PubMed ID: 26809719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics.
    Koutsaki M; Spandidos DA; Zaravinos A
    Cancer Lett; 2014 Sep; 351(2):173-81. PubMed ID: 24952258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer.
    Gao W; Xu J; Shu YQ
    Expert Rev Respir Med; 2011 Oct; 5(5):699-709. PubMed ID: 21955239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. microRNA and Ovarian Cancer.
    Langhe R
    Adv Exp Med Biol; 2015; 889():119-51. PubMed ID: 26659000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-small-cell lung cancer and miRNAs: novel biomarkers and promising tools for treatment.
    Feng B; Zhang K; Wang R; Chen L
    Clin Sci (Lond); 2015 May; 128(10):619-34. PubMed ID: 25760961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.
    Puerta-Gil P; García-Baquero R; Jia AY; Ocaña S; Alvarez-Múgica M; Alvarez-Ossorio JL; Cordon-Cardo C; Cava F; Sánchez-Carbayo M
    Am J Pathol; 2012 May; 180(5):1808-15. PubMed ID: 22426337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNAs regulate several functions of normal tissues and malignancies.
    Wen KC; Sung PL; Yen MS; Chuang CM; Liou WS; Wang PH
    Taiwan J Obstet Gynecol; 2013 Dec; 52(4):465-9. PubMed ID: 24411027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional role and prognostic significance of CD157 in ovarian carcinoma.
    Ortolan E; Arisio R; Morone S; Bovino P; Lo-Buono N; Nacci G; Parrotta R; Katsaros D; Rapa I; Migliaretti G; Ferrero E; Volante M; Funaro A
    J Natl Cancer Inst; 2010 Aug; 102(15):1160-77. PubMed ID: 20639476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miRNAs as molecular biomarkers of cancer.
    Fabbri M
    Expert Rev Mol Diagn; 2010 May; 10(4):435-44. PubMed ID: 20465498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical relevance of circulating cell-free microRNAs in ovarian cancer.
    Nakamura K; Sawada K; Yoshimura A; Kinose Y; Nakatsuka E; Kimura T
    Mol Cancer; 2016 Jun; 15(1):48. PubMed ID: 27343009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer.
    Zandberga E; Kozirovskis V; Ābols A; Andrējeva D; Purkalne G; Linē A
    Genes Chromosomes Cancer; 2013 Apr; 52(4):356-69. PubMed ID: 23404859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
    Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
    Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.
    Mandilaras V; Vernon M; Meryet-Figuière M; Karakasis K; Lambert B; Poulain L; Oza A; Denoyelle C; Lheureux S
    Expert Opin Biol Ther; 2017 Aug; 17(8):927-943. PubMed ID: 28641048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets.
    Kuznetsov VA; Tang Z; Ivshina AV
    BMC Genomics; 2017 Oct; 18(Suppl 6):692. PubMed ID: 28984201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The modularity and dynamicity of miRNA-mRNA interactions in high-grade serous ovarian carcinomas and the prognostic implication.
    Zhang W; Edwards A; Fan W; Flemington EK; Zhang K
    Comput Biol Chem; 2016 Aug; 63():3-14. PubMed ID: 26949157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.